# Cholinergic Anti-inflammatory Pathway in Prevention & Treatment of the SIRS in Patients With Jaundice After Operation.

> **NCT02279147** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Wanqing Gu** · enrollment: 100 (estimated)

## Conditions studied

- Systemic Inflammatory Response Syndrome
- Jaundice, Obstructive

## Interventions

- **DRUG:** neostigmine methylsulfate，raceanisodamine hydrochloride

## Key facts

- **NCT ID:** NCT02279147
- **Lead sponsor:** Wanqing Gu
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-08
- **Primary completion:** 2017-08
- **Final completion:** 2017-09
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2014-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02279147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02279147, "Cholinergic Anti-inflammatory Pathway in Prevention & Treatment of the SIRS in Patients With Jaundice After Operation.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02279147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*